754 related articles for article (PubMed ID: 17346298)
21. Soluble adhesion molecules in pediatric rheumatic diseases.
Bloom BJ; Miller LC; Blier PR
J Rheumatol; 2002 Apr; 29(4):832-6. PubMed ID: 11950029
[TBL] [Abstract][Full Text] [Related]
22. [Laboratory and morphologic parameters in patients with lupus nephritis].
Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
[TBL] [Abstract][Full Text] [Related]
23. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
Mak A; Cheung BM; Mok CC; Leung R; Lau CS
Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities.
Kuryliszyn-Moskal A; Klimiuk PA; Sierakowski S; Ciołkiewicz M
Arch Immunol Ther Exp (Warsz); 2007; 55(3):179-85. PubMed ID: 17557150
[TBL] [Abstract][Full Text] [Related]
25. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
Ezzat M; El-Gammasy T; Shaheen K; Shokr E
Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
[TBL] [Abstract][Full Text] [Related]
26. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
Morgan PE; Sturgess AD; Davies MJ
Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
[TBL] [Abstract][Full Text] [Related]
27. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
[TBL] [Abstract][Full Text] [Related]
28. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
Figueredo MA; Rodriguez A; Ruiz-Yagüe M; Romero M; Fernandez-Cruz A; Gomez-de la Concha E; Patiño R
J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
[TBL] [Abstract][Full Text] [Related]
29. Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus.
Robak E; Kulczycka L; Sysa-Jedrzejowska A; Wierzbowska A; Robak T
Eur Cytokine Netw; 2007 Dec; 18(4):181-7. PubMed ID: 17964973
[TBL] [Abstract][Full Text] [Related]
30. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.
Tripathy R; Panda AK; Das BK
Lupus; 2015 Jan; 24(1):82-9. PubMed ID: 25253568
[TBL] [Abstract][Full Text] [Related]
31. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Liu ZC; Zhou QL; Li XZ; Yang JH; Ao X; Veeraragoo P; Zuo XX
Cytokine; 2011 Mar; 53(3):295-300. PubMed ID: 21163672
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
33. Prolactin hormone in juvenile systemic lupus erythematosus: a possible relationship to disease activity and CNS manifestations.
El-Garf A; Salah S; Shaarawy M; Zaki S; Anwer S
J Rheumatol; 1996 Feb; 23(2):374-7. PubMed ID: 8882050
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
35. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
[TBL] [Abstract][Full Text] [Related]
36. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus.
Su Y; Jia RL; Han L; Li ZG
Clin Immunol; 2007 Jan; 122(1):115-20. PubMed ID: 17085075
[TBL] [Abstract][Full Text] [Related]
37. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
[TBL] [Abstract][Full Text] [Related]
38. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE).
Schiffer L; Kümpers P; Davalos-Misslitz AM; Haubitz M; Haller H; Anders HJ; Witte T; Schiffer M
Nephrol Dial Transplant; 2009 Dec; 24(12):3708-12. PubMed ID: 19602475
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
40. Complement degradation product C3d in urine: marker of lupus nephritis.
Negi VS; Aggarwal A; Dayal R; Naik S; Misra R
J Rheumatol; 2000 Feb; 27(2):380-3. PubMed ID: 10685801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
